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Sir,
We read with great interest the article by Arnould et al (2006). In
their study, they investigated by immunohistochemistry (IHC)
immune cell response during neoadjuvant primary systemic
therapy with trastuzumab and docetaxel in patients with IHC
3þ HER2-positive primary breast cancer. Trastuzumab treatment
was associated with significantly increased numbers of tumour-
associated NK cells and lymphocyte expression of granzyme B and
TiAI compared with controls. This suggests that trastuzumab plus
taxanes lead to enhanced NK cell activity, thus confirming that NK
cell activity via antibody-dependent cellular cytotoxicity (ADCC) is
one of the mechanisms of action of trastuzumab, as similarly
reported in vivo by other authors (Repka et al, 2003; Gennari et al,
2004). Furthermore, this observation may partially account for the
synergistic activity of trastuzumab and docetaxel in breast cancer.
In fact, taxanes lead to increased serum concentrations of some
cytokines and enhancement of NK cell activity (Tsavaris et al,
2002).
Moving from the same considerations, along with the observa-
tion that graft-versus-tumour responses in metastatic breast
cancer amount to 25–40% following nonmyeloablative allogeneic
haemopoietic stem cell transplantation (NST) (Bishop, 2004), and
that recognition by donor immune cells of minor histocompat-
ibility antigens and tumour-specific and/or overexpressed antigens
is the theoretical background for these alloimmune responses, we
treated two patients with IHC 3þ HER2-positive metastatic
progressive breast cancer with weekly trastuzumab administra-
tions (4mgkg
 1 intravenously (i.v.) the first dose, 2mgkg
 1 i.v.
the other doses) in case of disease progression (PD) following NST.
In fact, we hypothesised that the use of antitumoral monoclonal
antibodies (moAbs) (such as trastuzumab) following NST might
enhance the allogeneic ADCC against tumour cell targets, possibly
avoiding undesirable graft-versus-host reactions; conversely, a
cellular component might enhance the effects of antitumoral
moAbs and vaccines directed against the HER2 antigen (Reilly
et al, 2001; Disis et al, 2002; zum Buschenfelde et al, 2002; Wolpoe
et al, 2003). Patients were treated in a clinical trial approved by an
independent ethical committee and in accordance with the
Helsinki Declaration. Written informed consent was obtained
from the two patients before enrolment.
Patients were aged 40 and 49 years, respectively. Both were
heavily pretreated with five and three chemotherapy lines
(including docetaxel), respectively. Trastuzumab, radiotherapy
and several hormonal treatments were administered to both
patients and both had PD at the time of transplant; the first one
had bone and liver metastases, and the second liver metastases.
Doses of 8.0 and 5.0 10
6kg
 1 lenograstim-stimulated CD34þ
cells were given to the two patients, respectively, in both cases
from an HLA-identical sibling (on day 0) following a reduced-
intensity conditioning with thiotepa 10 and 5mgkg
 1 i.v.,
cyclophosphamide 120mgkg
 1 i.v. and fludarabine 120mgm
 2
i.v. Graft-versus-host disease (GVHD) prophylaxis consisted of
cyclosporin A and short-course methotrexate.
Neutrophils and platelets engraftment were rapidly achieved on
days þ13/þ10 and þ9/þ11 after NST, respectively. Stable full
donor chimerism (FDC) (by PCR analysis) on total cells was
reached on day þ28 in both patients. On separated peripheral
myeloid and lymphoid cells, stable FDC was achieved on day þ28
in the first patient and on days þ130 and þ170, respectively, in
the second patient. Lymphoid FDC was reached following the first
donor lymphocyte infusion (DLI) on day þ140 in the second
patient.
The first patient started weekly trastuzumab administrations on
day þ48, because of early liver PD. However, no disease response
and/or GVHD were observed and the patient eventually died of
liver PD 6 months later.
The second patient developed on day þ71 grade 3 liver failure
(according to NCI criteria v3.0) with jaundice, in the absence of
other clinical signs of acute GVHD but with liver and right breast
PD evidence. The patient was hospitalised and weekly trastuzumab
was started. Trastuzumab resulted in a rapid decrease of serum
bilirubin, transaminases, jaundice and hepatomegaly. Right breast
recurrence disappeared, but subsequent liver PD was shown by
a CT scan on day þ98. Two DLIs were then administered on
day þ140 (dose of 1 10
6 CD3þ kg
 1) and on day þ178 (dose
of 1 10
7 CD3þ kg
 1), and 24h later, the 10th and the 14th
trastuzumab administration, respectively. On day þ154, left
sovraclavear nodes and right breast PD, along with an increase
of CEA and CA15.3 serum markers and the development of a grade
4 liver failure occurred. A Kehr drain was positioned. On day
þ195, weekly paclitaxel 60mg i.v. was added to trastuzumab,
resulting in liver partial remission (PR) on day þ288 (Figure 1)
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drain was removed on day þ364. No signs of chronic GVHD
were observed. The patient remained well and in PR until
day þ405, when liver PD reoccurred. Chemotherapies with
gemcitabine, carboplatin and capecitabine were sequentially
added to trastuzumab, but they were ineffective and the patient
died on day þ658. Of note, an increase of CD8þCD3þ cytotoxic
T cells and CD16þCD56þ NKs was observed after NST by
immunophenotypical blood T- and B-cell analysis, and a
CD19þ cells peak was registered after the start of trastuzumab
(see Table 1).
Even though this is not direct evidence to support the role
of an allogeneic ADCC, the regression of severe liver impairment
owing to liver PD by the administration of trastuzumab after
NST, the subsequent disease response by the addition of
paclitaxel to trastuzumab in a patient who had been heavily
pretreated with several drugs including docetaxel and trastuzu-
mab, and the concomitant increase of NK cells and CTLs in
peripheral blood might support the observation of Arnould et al
(2006) and suggest further researches to validate the hypothesis
of a synergistic cytotoxicity with combined immuno- and
chemotherapy.
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